Sectors
MBX
MBX Biosciences, Inc. Common Stock
58.58
1 x 58.11
1 x 58.66
bid
ask
-
1.70
2.82%
09:59 AM
timesize
| Ytd | 85.73% | |
| 1y | 400.69% |
59.20
day range
60.65
9.63
52 week range
66.55
| Open | 60.18 | Prev Close | 60.28 | Low | 59.20 | High | 60.65 | Mkt Cap | 2.02B |
| Vol | 28.61K | Avg Vol | 846.54K | EPS | -2.21 | P/E | -27.28 | Forward P/E | -15.54 |
| Beta | 0.16 | Short Ratio | 5.62 | Inst. Own | 120.25% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 43.54 | 200-d Avg | 33.08 | 1yr Est | 69.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-06 | 2026-06 | -0.68 | N/A | N/A | N/A |
| 2026-05-07 | 2026-03 | -0.62 | -0.51 | 0.11 | 17.74% |
| 2026-03-12 | 2025-12 | -0.64 | -0.49 | 0.15 | 23.44% |
| 2025-11-06 | 2025-09 | -0.73 | -0.63 | 0.1 | 13.70% |
| 2025-08-07 | 2025-06 | -0.77 | -0.58 | 0.19 | 24.68% |
| 2025-05-12 | 2025-03 | -0.81 | -0.71 | 0.1 | 12.35% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-05-12 | Barclays | Upgrade | Overweight | Overweight |
| 2026-05-12 | Citizens | Upgrade | Market Outperform | Market Outperform |
| 2026-05-11 | Truist Securities | Upgrade | Buy | Buy |
| 2026-01-28 | Barclays | Upgrade | Overweight | |
| 2026-01-16 | Guggenheim | Upgrade | Buy | Buy |
| 2026-01-07 | UBS | Upgrade | Buy |
Profile
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-09-15 | BASKETT FOREST | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2024-09-15 | BEHBAHANI ALI | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2024-09-15 | CHANG CARMEN | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2024-09-15 | FRAZIER LIFE SCIENCES X, L.P. | Beneficial Owner of more than 10% of a Class of Security | 4.55M | Purchase |
| 2025-02-17 | GORDON CARL L | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2025-09-25 | HERON PATRICK J | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | Frazier Life Sciences Management, L.P. | 6.65M | 0.00 | 13.98% |
| 2026-03-30 | Orbimed Advisors, LLC | 3.64M | 0.00 | 7.64% |
| 2026-03-30 | NEA Management Company, LLC | 3.61M | 0.00 | 7.59% |
| 2026-03-30 | Wellington Management Company LLP | 3.19M | 0.00 | 6.71% |
| 2026-03-30 | BlackRock Inc | 2.94M | 0.00 | 6.18% |
| 2026-03-30 | FMR Inc | 2.94M | 0.00 | 6.17% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-05-30 | Polar Capital Biotech S Inc | 1.52M | 0.00 | 3.20% |
| 2026-06-29 | Vanguard Total Stock Mkt Idx Inv | 1.14M | 0.00 | 2.39% |
| 2026-03-30 | Eventide Healthcare & Life Sciences I | 890.00K | 0.00 | 1.87% |
| 2026-06-29 | iShares Russell 2000 ETF | 801.38K | 0.00 | 1.68% |
| 2026-05-30 | Fidelity Select Health Care | 600.00K | 0.00 | 1.26% |
| 2026-06-29 | T. Rowe Price Health Sciences | 586.31K | 0.00 | 1.23% |